Key Highlights
- Biohaven (NYSE:BHVN) announced on October 8, 2026 a deal with Ono Pharmaceutical: USD 80 million upfront, a USD 20 million milestone expected within about a year and royalties of roughly 20% in Japan and select Asian markets.
- Viatris (NASDAQ:VTRS) has an FDA goal date of October 17, 2026 for MR-141, phentolamine ophthalmic solution 0.75%, in presbyopia, backed by two Phase 3 trials that, per the company, met their primary and all key secondary endpoints with no serious adverse events.
- Opus Genetics (NASDAQ:IRD) held USD 88.8 million of cash at June 30, 2026, expects funding into 2029, and saw shares outstanding rise about 18% in six months to 82,647,946, a dilution cost to existing shareholders.
- Merck (NYSE:MRK) and Daiichi Sankyo withdrew the ifinatamab deruxtecan application on September 25, 2026, so no FDA decision is expected on the previously listed October 10 date, and no efficacy numbers were released.
Biohaven (NYSE:BHVN): A Licensing Windfall
Biohaven (NYSE:BHVN) licensed its MoDE pan-IgG degrader portfolio, BHV-1300, BHV-1310 and BHV-1320, to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries on October 8, 2026. It receives USD 80 million at signing, a USD 20 million milestone expected within about a year and royalties of roughly 20% of Ono's net sales. Biohaven keeps the US, Europe and China. BHV-1300 is in Phase 3 for Graves' disease, and Phase 1 showed total IgG reductions of up to 87% with subcutaneous dosing. The mechanism directs IgG toward the liver for degradation through the ASGPR receptor. The risk for Biohaven (NYSE:BHVN) is Phase 3 failure, since royalties depend on approvals and sales years away. Chief executive Vlad Coric called Ono the ideal partner to bring this immune-modulating technology to patients, and Ono president Toichi Takino said the company looks forward to advancing the development program. J.P. Morgan and Sullivan & Cromwell advised Biohaven. The release gave no Phase 3 design, enrollment or timelines, so the path to approval in Asia remains uncertain. The row summarizing the deal named only BHV-1300, but the release covers three candidates, and no share price reaction was verified.
Viatris (NASDAQ:VTRS): An Eye Drop Decision
Viatris (NASDAQ:VTRS) announced on February 25, 2026 that the FDA accepted its supplemental application for MR-141, phentolamine ophthalmic solution 0.75%, for presbyopia, with a goal date of October 17, 2026. The drug is already sold as Ryzumvi to reverse pharmacologically induced pupil dilation, and approval would broaden the label to age-related loss of near focusing. The company said Phase 3 trials VEGA-2 and VEGA-3 met their primary and all key secondary endpoints with no treatment-related serious adverse events, but gave no patient numbers. Viatris holds exclusive US commercialization rights. The FDA can approve, issue a complete response letter or extend review, and Viatris (NASDAQ:VTRS) must still win Demand if approved. Philippe Martin, chief Research and Development officer at Viatris, said the company is confident in the strength of the clinical data supporting the submission. For Ryzumvi, common adverse reactions were instillation site discomfort in 16% of patients, conjunctival hyperemia in 12% and dysgeusia, a taste change, in 6%. A calendar summary reported that presbyopia affects about 90% of US adults over 45, a figure not checked against a company source. The release did not give patient numbers or the share of patients who gained lines of near vision, so the size of the benefit is unknown, and no update to the October 17 date has been found since February.
Opus Genetics (NASDAQ:IRD): Cash and Dilution
Opus Genetics (NASDAQ:IRD) reported second quarter results on August 6, 2026 with USD 88.8 million of cash versus USD 45.1 million at year end 2025, a net loss of USD 8.1 million and research expense of USD 11.2 million. It expects cash to fund operations into 2029 excluding Warrant proceeds and milestones. Shares outstanding rose to 82,647,946 from 69,894,507, about 18% higher by simple arithmetic, and warrant liabilities were USD 62.1 million. The lead gene therapy OPGx-LCA5 has a registrational Phase 3 trial of eight participants with dosing expected in the fourth quarter of 2026. Opus is party to the Viatris licensing agreement, whose terms were not disclosed, so the October 17 date is an unquantified catalyst. Research and development expense rose to USD 11.2 million from USD 6.0 million on Manufacturing and clinical costs, and license and collaboration Revenue fell to USD 0.8 million from USD 2.9 million. Warrants are carried at fair value, producing a USD 44.2 million loss in the first half of 2026. OPGx-BEST1 three-month data were due in September 2026, but the result was not verified. Chief executive George Magrath said the company is advancing five gene therapy programs.
Merck (NYSE:MRK): A Withdrawn Filing
Merck (NYSE:MRK) and Daiichi Sankyo withdrew the Biologics license application for ifinatamab deruxtecan in extensive-stage small cell lung cancer on September 25, 2026 after FDA discussions. The companies concluded that the data, including the 187-patient IDeate-Lung01 Phase 2 trial, do not meet the requirements for Accelerated Approval for the proposed indication. No efficacy numbers were released. The Phase 3 IDeate-Lung02 trial is nearly fully enrolled and could support a new filing, while two other Phase 3 trials continue. A calendar summary still listed October 10, but no decision is expected. This is a delay, not an end, for Merck (NYSE:MRK). IDeate-Lung01 randomized patients to 8 mg/kg or 12 mg/kg every three weeks before expanding at 12 mg/kg, with response rate by blinded independent review as the primary endpoint. Marjorie Green of Merck Research Laboratories said the companies were disappointed the dataset did not support approval at this time. IDeate-Lung02 compares the drug with physician's choice chemotherapy, and IDeate-Prostate01 and IDeate-Esophageal01 are also ongoing. The stock reaction was not verified.
Where Things Stand
The four companies show that biotech catalysts come in different forms: cash from a licensing deal, a regulatory decision, a financing-dependent pipeline and a withdrawn application. Biohaven (NYSE:BHVN) has the clearest near-term cash. Viatris has the nearest dated event, Opus Genetics (NASDAQ:IRD) carries dilution risk and Merck faces a delay. October 17 is the date to watch for Viatris and its partner Opus Genetics, and none of these outcomes is guaranteed. Investors should check each company's filings for updates, since dates in this article come from releases that may have changed since publication.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...